21st International Congress » Parkinson's Disease: Neuroimaging And Neurophysiology

1:15pm-2:45pm

Pathway Selective Deep Brain Stimulation Derived from Patient-Specific Models

K. Gunalan, B. Howell, R. Patriat, Y. Duchin, G. Sapiro, N. Harel, C. McIntyre (Cleveland, OH, USA)

1:15pm-2:45pm

[18F]-AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP

S. Coakeley, S.S. Cho, Y. Koshimori, P. Rusjan, A. Lang, S. Houle, A. Strafella (Toronto, ON, Canada)

1:15pm-2:45pm

18F-AV-1451 PET imaging in pre-dementia Parkinson’s disease

A. Hansen, M. Damholdt, K. Knudsen, T. Fedorova, K. Østergaard, D. Brooks, P. Borghammer (Aarhus C, Denmark)

1:15pm-2:45pm

18F-labeled FP-CIT PET Findings in a series of cirrhotic patients with parkinsonism

H.-J. Yang, S.H. Park, Y. Kim (Ulsan, Republic of Korea)

1:15pm-2:45pm

99mTc-TRODAT-1 SPECT imaging in early and late onset Parkinson’s disease.

A. Ghabeli Juibary, V.R. Dabbagh Kakhki, P. Sasannejad, R. Sadeghi, K. Sadri, M. Sabour, H. Alizadeh (Mashhad, Islamic Republic of Iran)

1:15pm-2:45pm

A follow-up study of hyperechogenicity of the substantia nigra in Parkinson’s disease and atypical parkinsonian syndrome

J. Horie, H. Fujita, K. Suzuki, A. Numao, Y. Watanabe, T. Matsubara, T. Uchiyama, T. Miyamoto, M. Miyamoto, T. Kadowaki, K. Hirata (Shimotsuga-gun, Japan)

1:15pm-2:45pm

A neuroimaging-based model for disease progression in Parkinson’s disease

N. Shenkov, I. Klyuzhin, A. Rahmim, V. Sossi (Vancouver, BC, Canada)

1:15pm-2:45pm

A quantitative meta-analysis study of Impulse control disorders in patients with and without Parkinson’s Disease.

A. Faust- Socher, M. Criaud, A. Mihaescu, A. Lang, S. Cho, S. Houle, A. Strafella (Toronto, ON, Canada)

1:15pm-2:45pm

Aberrant resting state functional brain networks in patients with Parkinson’s disease and visual hallucinations

A. Lenka, R. Panda, L. George, S. Hegde, S. Arumugham, J. Saini, R. Bharath, P. Pal (Bangalore, India)

1:15pm-2:45pm

Abnormal DaTscan in a case of Anoxic brain injury

S. Byreddy, U. Zahid, H. Lei (Tucson, AZ, USA)

1:15pm-2:45pm

Abnormal spontaneous activity and functional connectivity in patients with Parkinson’s disease with anxiety

M. Criaud, M. Zurowski, N. Lobaugh, S. Chavez, Y. Koshimori, A. Lang, S. Houle, A. Strafella (Toronto, ON, Canada)

1:15pm-2:45pm

Action Observation Training Effects on Brain Structural and Functional Changes in Parkinson’s Disease Patients

E. Sarasso, F. Agosta, M. Di Meo, M. Giacobbe, M.A. Volonté, G. Comi, A. Tettamanti, R. Gatti, M. Filippi (Milan, Italy)

1:15pm-2:45pm

Alterations in Dynamic Brain Connectivity Patterns in Parkinson’s Disease

X. Dan, A. Liu, J. Wang, M. McKeown, T. Wu, P. Chan (Beijing, China)

1:15pm-2:45pm

Altered attentional brain network in Parkinson’s disease with mild cognitive impairment

J.H. Yang, K. McMahon, D. Copland, G. Byrne, A. Toft, L. Mithcell, J. O'Sullivan, N. Dissanayaka (Herston, Australia)

1:15pm-2:45pm

Altered intrinsic brain functional connectivity in drug-naïve Parkinson’s disease with LRRK2 mutation

Y. Hou, C. Luo, J. Yang, R. Ou, W. Song, Y. Chen, Q. Gong, H. Shang (Chengdu, China)

1:15pm-2:45pm

Altered PDE10A Expression Detectable Early in Untreated Parkinson’s Disease Patients

G. Pagano, F. Niccolini, H. Wilson, T. Yousaf, N. Khan, D. Martino, R. Gunn, E. Rabiner, M. Politis (London, United Kingdom)

1:15pm-2:45pm

Altered Resting-State Functional Interhemispheric Connectivity in Parkinson’s Disease

X. Dan, S. Lin, A. Liu, J. Wang, T. Wu, P. Chan, M. McKeown (Beijing, China)

1:15pm-2:45pm

Anxiety influences the neural correlates associated with freezing of gait in Parkinson’s disease

K. Ehgoetz Martens, M. Georgiades, M. Gilat, J. Hall, J. Shine, C. Walton, S. Lewis (Camperdown, Australia)

1:15pm-2:45pm

Assessing cholinergic innervation in Parkinson’s disease using the PET imaging marker [18F]Fluoroethoxybenzovesamicol

S. vander Zee, I. Alves, A. Willemsen, P. Elsinga, T. van Laar (Groningen, Netherlands)

1:15pm-2:45pm

Assessing Nigral Functional Connectivity in Parkinson’s Disease with Resting State Functional MRI

A. Martin-Bastida, Y. Xing, S. Pietracupa, A. Roussakis, N. Lao-Kaim, W. Li, X. Li, P. Mahlknecht, S. Schwarz, T. Foltynie, D. Auer, P. Piccini (London, United Kingdom)

1:15pm-2:45pm

Assessment of substantia nigra degeneration with magnetic resonance and transcranial ultrasonography

C. Prieto, V. Suárez, C. Ordás, B. Venegas, R. Cazorla, A. Vinagre (Valdemoro, Spain)

1:15pm-2:45pm

Associations of DAT SPECT and TCS with prodromal features of Parkinson’s disease: results in PREDICT-PD participants

A. Noyce, J. Dickson, J. Bestwick, I. Isaias, M. Politis, G. Giovannoni, T. Warner, A. Lees, A. Schrag (London, United Kingdom)

1:15pm-2:45pm

Beta oscillatory changes during practice and retention of motor skills in healthy subjects and patients with PD

A. Nelson (NY, USA)

1:15pm-2:45pm

Brain PET metabolic substrate of Impulse Control Disorders in Parkinson’s Disease

E. Robin, A. Verger, F. Fluchere, T. Witjas, J.P. Azulay, E. Guedj, A. Eusebio (Marseille, France)

1:15pm-2:45pm

Brain structural and functional changes associated with frequent falls in Parkinson’s disease

H. Otomune, M. Mihara, H. Fujimoto, Y. Kajiyama, K. Konaka, Y. Mitani, G. Revankar, H. Mochizuki (Suita, Japan)

1:15pm-2:45pm

Cardiac 123I-MIBG Scintigraphy, olfactory testing and transcranial sonography for differentiating between Parkinson’s disease and atypical parkinsonian syndromes during the early stage

h. fujita, K. Suzuki, A. Numao, Y. Watanabe, T. Uchiyama, T. Miyamoto, M. Miyamoto, T. Kadowaki, K. Hirata (Shimotsuga-gun, Japan)

1:15pm-2:45pm

Cardiac-related pulsatility in white matter is associated with cognitive and motor performance in patients with Parkinson’s disease

Z. Shirzadi, H. Sharmarke, A. Robertson, A. Metcalfe, S. Duff-Canning, C. Marras, A. Lang, M. Masellis, B. MacIntosh (Toronto, ON, Canada)

1:15pm-2:45pm

Central pain processing in “drug-naïve” pain-free patients with Parkinson’s disease

R. De Micco, A. Russo, F. Esposito, A. Giordano, M. Fratello, G. Caiazzo, M. Cirillo, G. Tedeschi, A. Tessitore (Naples, Italy)

1:15pm-2:45pm

Clinical and Imaging and phenoconversion in the PARS prodromal cohort

K. Marek, A. Siderowf, S. Eberly, D. Oakes, M. Stern, D. Russell, J. Seibyl, D. Jennings (New Haven, CT, USA)

1:15pm-2:45pm

Clinical characteristics of cognitive impairment in patients with Parkinson’s disease and its related pattern in 18F-FDG PET imaging

F.-t. Liu, J.-j. Ge, L. Wu, Y.-j. Yang, J. Zhao, S.-s. Luo, Y.-m. Sun, J.-j. Wu, Z.-t. Ding, C.-t. Zuo, J. Wang (Shanghai, China)

1:15pm-2:45pm

Clinical characteristics of scan without evidence of dopaminergic deficits (SWEDDs) in Japan.

M. Takahashi, Y. Tashiro, N. Ito, T. Sato, T. Sekiguchi, A. Inaba, S. Orimo (Tokyo, Japan)

1:15pm-2:45pm

Clinical Utility of Optimized Parameters for a Quantitative Analysis of 123I-ioflupane SPECT (DaTscan) Images

G. Zubal, S. Tinaz, C. Chow, H. Blumenfeld, E. Louis (New Haven, CT, USA)

1:15pm-2:45pm

Clinical utility of visualization of Nigrosome-1 in patients with Parkinson’s disease

A. Sunny, R. Naduthota, R. Botta, S. Varadharajan, J. Saini, R. Yadav, P. Pal (Bangalore, India)

1:15pm-2:45pm

Cognitive changes and cortical thinning evolution of parkinson’s disease patients: 4-year-follow up.

A. Campabadal, C. Uribe, B. Segura, H. Baggio, A. Abos, A. Garcia-Diaz, M.-J. Marti, Y. Compta, F. Valldeoriola, C. Junque (Barcelona, Spain)

1:15pm-2:45pm

Connectivity patterns in frontal cognitive regions in Parkinson’s disease

A. Hanganu, A. Nagano-Saito, A. Tam, N. Auclair-Ouellet, S. Jobert, B. Mejia-Constain, D. Schoemaker, C. Degroot, A.-L. Lafontaine, H. Chertkow, P. Bellec, O. Monchi (Calgary, AB, Canada)

1:15pm-2:45pm

Correlation analysis between dopamine release in striatal sub-regions and motor impairment in Parkinson’s disease subjects

I. Klyuzhin, M. Sacheli, N. Vafai, E. Shahinfard, B. Lakhani, J. Neva, J. Fu, J. McKenzie, N. Neilson, K. Dinelle, L. Boyd, A. Stoessl, V. Sossi (Vancouver, BC, Canada)

1:15pm-2:45pm

Cortical phase-amplitude coupling across Parkinson’s disease phenotypes measured with magnetoencephalograph

J. Bajwa, E. Peña, L. Rosedahl, T. Mohammed, F. Almohammed, T. AlOtaibi, L. Soualmi, V. Poghosyan, S. Cooper, V. Jousmäki, M. Johnson (Riyadh, Saudi Arabia)

1:15pm-2:45pm

Decreased Fronto-Parietal connection is associated with face pareidolia in Parkinson’s disease.

Y. Kajiyama, M. Mihara, Y. Mitani, H. Otomune, H. Fujimoto, G. Revankar, K. Konaka, H. Mochizuki (Osaka, Japan)

1:15pm-2:45pm

Deep Brain Stimulation of Subthalamic Nucleus Selectively Modulates Striato-Thalamo-Cortical Circuit in Parkinson’s Disease: a Systematic Review and ALE Meta-analysis

H. Chen (Beijing, China)

1:15pm-2:45pm

Differences in cerebral perfusion between Major depression disorder and depression with Parkinson’s disease : Brain HMPAO SPECT study using SPM analysis

Y.-D. Kim, Y.-D. Kim (Incheon, Republic of Korea)

1:15pm-2:45pm

Diffusion tensor imaging changes in the corpus callosum and cognitive impairment in Parkinson’s disease

I. Bledsoe, D. Merkitch, G. Stebbins, B. Bernard, J. Goldman (San Francisco, CA, USA)

1:15pm-2:45pm

Distinct pattern of striatal dopaminergic depletion in patients with parkin mutation

K.-Y. Kwon (Seoul, Republic of Korea)

1:15pm-2:45pm

Does smoking impact dopamine neuronal loss in de novo Parkinson’s disease?

Y. Lee, H.s. Yoo, S.J. Chung, P.H. Lee, Y.H. Sohn (Seoul, Republic of Korea)

1:15pm-2:45pm

Dopamine depletion impairs gait automaticity by altering cortico-striatal and cerebellar processing in Parkinson’s disease

M. Gilat, P. Bell, K. Ehgoetz Martens, M. Georgiades, J. Hall, C. Walton, S. Lewis, J. Shine (Sydney, Australia)

1:15pm-2:45pm

Dopamine Normalizes Putamen to Insula Activation Shift During Choice Reaction Time Task in PD

J. Kim, K. Zhang, S. YorkWilliams, M. Ua Cruadhlaoich, V. Menon, K. Poston (Palo Alto, CA, USA)

1:15pm-2:45pm

Dopamine transporter imaging predicts motor response to dopaminergic therapy for patients with advanced Parkinson’s disease: Possible role in patient selection for subthalamic deep brain stimulation.

A. Nakajima, Y. Shimo, S. Sekimoto, K. Kamagata, J. Takayuki, G. Oyama, A. Umemura, N. Hattori (Tokyo, Japan)

1:15pm-2:45pm

Early caudate involvement in Parkinson’s disease may predict future cognitive decline

R. Durcan, D. Brooks, D. Burn, N. Pavese (Newcastle Upon Tyne, United Kingdom)

1:15pm-2:45pm

Early cognitive impairment phenotype and functional connectivity in non-demented Parkinson’s disease patients

K. Kawabata, H. Watanabe, K. Hara, E. Bagarinao, N. Yoneyama, A. Ogura, K. Imai, M. Masuda, T. Yokoi, R. Ohdake, T. Tsuboi, M. Ito, N. Atsuta, M. Katsuno, G. Sobue (Nagoya, Japan)

1:15pm-2:45pm

EEG Markers for Emotional Inhibition in Parkinson’s Disease

N. Dissanayaka, D. Hennessy, T. Au, A. Angwin, J.H. Yang, J. O'Sullivan, D. Copland (Brisbane, Australia)

1:15pm-2:45pm

EEG Shows Subclinical Motor Preparation Deficits in Parkinson’s Disease Patients with Freezing of Gait During Locomotion

C. Fearon, J. Butler, S. Waechter, I. Killane, L. Newman, T. Munteanu, D. Birsanu, B. Magennis, R. Reilly, T. Lynch (Dublin 7, Ireland)

1:15pm-2:45pm

Evaluation of Brainstem Auditory Evoked Response and Nerve Conduction in Parkinson’s Disease

D. AGRAWAL, N. AHMED, A. CHUGHTAI (ALIGARH-202002, India)

1:15pm-2:45pm

Evaluation of SV2A expression with [18F]MNI-944 PET imaging in healthy controls (HC) and Parkinson disease (PD)

D. Russell, D. Alagille, V. Carroll, M. Thompson, J. Madonia, O. Barret, C. Constantinescu, J. Seibyl, K. Marek, G. Tamagnan (New Haven, CT, USA)

1:15pm-2:45pm

Evolution in Dopamine Transporter (DaT) Scan Utilization Patterns and its Effect on Treatment Decisions:  Results of the Next 200 Scans

X.X. Yu (Cleveland, OH, USA)

1:15pm-2:45pm

Exercise alters response of reward anticipation in the ventral striatum of subjects with Parkinson’s disease

M. Sacheli, D. Murray, N. Vafai, E. Shahinfard, M. Cherkasova, K. Dinelle, N. Neilson, J. McKenzie, S. Appel-Cresswell, M. McKeown, V. Sossi, A. Stoessl (Vancouver, BC, Canada)

1:15pm-2:45pm

F-18-DOPA-PET predicts impulsive behavior under dopaminergic therapy in Parkinson patients

J. Hammes, M. Tittgemeyer, C. Eggers, A. Drzezga, T. van Eimeren (Cologne, Germany)

1:15pm-2:45pm

Functional Connectivity Differences Across Parkinson Disease Subtypes

M. Campbell, C. Gratton, J. Koller, W. Shannon, C. Lessov-Schlaggar, S. Petersen, J. Perlmutter (St. Louis, MO, USA)

1:15pm-2:45pm

Functional MAOB gene intron 13 polymorphism predicts putaminal dopamine turnover in de novo Parkinson’s disease

M. Löhle, G. Mangone, M. Wolz, B. Beuthien-Baumann, L. Oehme, J. Hoff, J. Kotzerke, H. Reichmann, J.-C. Corvol, A. Storch (Rostock, Germany)

1:15pm-2:45pm

Functional role of the cerebellum in Parkinson’s disease : a PET-Study

A. Riou, F. Le Jeune, J.-F. Houvenaghel, S. Drapier, M. Vérin, G. Robert (RENNES, France)

1:15pm-2:45pm

Gait asymmetry in people with Parkinson’s disease is linked to reduced integrity of callosal sensorimotor regions

F. Horak, C. Curtze, B. Fling (Portland, OR, USA)

1:15pm-2:45pm

Global Regulatory Agencies Support the Use of Dopamine Transporter Neuroimaging for Subject Selection in Clinical Trials Targeting Early Stage Parkinson’s Disease – on behalf of Critical Path for Parkinson’s (CPP) Consortium

D. Stephenson, J. Cedarbaum, J. Eberling, M. Facheris, D. Grosset, M. Gordon, D. Hill, S. Imam, V. Kern, G. Klein, D. Matthews, P. Muglia, A. Roach, K. Romero, D. Russell, J. Seibyl, L. Slieker, E. Somer, C. Sur, Z. Xie, K. Marek (Tucson, AZ, USA)

1:15pm-2:45pm

Globus Pallidus and Pedunculopontine Nucleus Oscillations during Executed and Imagined Gait in Patient with Parkinson’s Disease and Freezing of Gait Symptoms.

E. Opri, R. Molina, J. Shute, K. Foote, M. Okun, A. Gunduz (Gainesville, FL, USA)

1:15pm-2:45pm

Grey matter abnormalities associated with early cognitive decline in Parkinson’s disease

A. Moonen, R. Lopes, A. Leentjens, A. Duits, K. Dujardin (Maastricht, Netherlands)

1:15pm-2:45pm

High-Pass Filtered Phase MR Imaging to Detect Longitudinal Motor Associations of Iron Accumulation in Parkinson’s Disease

A. Martin-Bastida, N. Lao-Kaim, Y. Xing, C. Loane, A. Roussakis, S. Schwarz, N. Valle-Guzman, P. Mahlknecht, X. Li, G. Paul-Visse, H. Widner, M. Politis, T. Foltynie, R. Barker, D. Auer, P. Piccini (London, United Kingdom)

1:15pm-2:45pm

Hippocampal iron deposition in Parkinson disease and Parkinson disease with dementia/Lewy body dementia: quantitative susceptibility mapping assessments

M. Miyata, S. Kakeda, J. Moriya, H. Narimatsu, T. Sato, H. Adachi, Y. Wang, Y. Korogi (Kitakyushu, Japan)

1:15pm-2:45pm

Hypertension and Parkinson’s disease

B. Giordano, G. Pagano, J. Hood, N. Ferrara, M. Politis (London, United Kingdom)

1:15pm-2:45pm

Hypometabolism in Orbitofrontal and Perirhinal Cortex is Associated with Impulse Control Disorder in Parkinson´s Disease

I. Navalpotro-Gomez, A. Botas-Peñín, F. Molinet-Dronda, C. Gasca-Salas, M. Carmona-Abellán, H. Jiménez-Urbieta, M. Delgado-Alvarado, A. Quiroga-Varela, B. Gago, M.C. Rodríguez-Oroz (San Sebastian, Spain)

1:15pm-2:45pm

Impacts of White Matter Hyperintensities on Limit of Stability in Drug-naïve, de novo Patients with Idiopathic Parkinson’s Disease

J.-H. Park, S.-K. Lee, T.-K. Lee (Bucheon-si, Republic of Korea)

1:15pm-2:45pm

Impaired sensorimotor and visual networks in drug naive Parkinson’s disease based on graph theoretical analysis

H. Chen (Beijing, China)

1:15pm-2:45pm

Improvement of memory guided saccade amplitude by the STN DBS and target eccentricity

A. YUGETA, Y. TERAO, Y. UGAWA (Tokyo, Japan)

1:15pm-2:45pm

In vivo mapping of nigro-striatal dopamine transporter (DAT) availability in early Parkinson´s disease patients using [18F]FE-PE2I and high-resolution positron emission tomography.

P. Fazio, P. Svenningsson, Z. Cselenyi, C. Halldin, L. Farde, A. Varrone (Stockholm, Sweden)

1:15pm-2:45pm

Increased hippocampal activation in Parkinson’s disease related amnestic mild cognitive impairment

K. Perepezko, A. Gold, A. Bakker, G. Pontone, C. Speck, L. Rosenthal (Baltimore, MD, USA)

1:15pm-2:45pm

Interactions between amyloid-β and microglial activation in Parkinson’s disease

C. Ghadery, Y. Koshimori, J. Kim, S. Coakeley, M. Harris, L. Christopher, P. Rusjan, A. Lang, S. Houle, A. Strafella (Toronto, ON, Canada)

1:15pm-2:45pm

Link between striatal dopamine uptake and cortical dysconnectivity in Parkinson’s disease

A. Greuel, M. Tahmasian, F. Schwartz, S. Aschenberg, F. Maier, L. Timmermann, A. Drzezga, M. Tittgemeyer, C. Eggers (Cologne, Germany)

1:15pm-2:45pm

Longitudinal comparison of 11C-PE2I and 18F-DOPA PET for assessing severity and rate of disease progression in patients with Parkinson’s disease

W. Li, N. Lao-Kaim, A.-A. Roussakis, A. Martin-Bastida, C. Loane, N. Valle-Guzman, Z. Kefalopoulou, M. Politis, T. Foltynie, R. Barker, P. Piccini (London, United Kingdom)

1:15pm-2:45pm

Longitudinal Cortical Thickness Changes in GBA-Positive Relative to GBA-negative Parkinson’s Disease Patients with Hemiparkinsonism

I. Stankovic, N. Kresojevic, F. Agosta, V. Markovic, E. Sarasso, P. Valsasina, I. Petrovic, M. Filippi, V. Kostic (Belgrade, Serbia)

1:15pm-2:45pm

Longitudinal white matter microstructural change in Parkinson’s disease

C. Gallagher, V. Pozorski, J. Oh, F. Theisen, N. Adluru, A. Alexander (Madison, WI, USA)

1:15pm-2:45pm

Marked occipital hypometabolism on FDG-PET in patients with idiopathic RBD may predict Parkinson’s disease

K. Kashihara, M. Kitayama, T. Hamaguchi (Okayama, Japan)

1:15pm-2:45pm

Metabolic changes following transcranial magnetic resonance-guided focused ultrasound subthalamotomy

R. Rodriguez-Rojas, R. Martinez-Fernandez, J. Pineda-Pardo, C. Sanchez-Catasus, M. del Alamo, J. Obeso (Mostoles, Spain)

1:15pm-2:45pm

Modulation of executive motor network after neurofeedback training in Parkinson’s disease

N. Smulders, D. Mehler, L. Subramanian, D. Linden, J. Whittaker (Cardiff, United Kingdom)

1:15pm-2:45pm

Morphometric changes in Parkinson’s disease manifesting freezing of gait

S. Pietracupa, A. Suppa, N. Upadhyay, A. Zampogna, F. Di Biasio, G. Grillea, N. Modugno, G. Fabbrini, A. Berardelli, P. Pantano (Pozzilli, Italy)

1:15pm-2:45pm

Multicenter Validation of Disease- related Parkinson’s disease pattern with Resting State functional MRI

K. Schindlbeck, A. Vo, Y. Ma, S. Peng, K. Poston, H. Hurtig, N. Dahodwala, D. Eidelberg (Manhasset, NY, USA)

1:15pm-2:45pm

Neural correlates of minor hallucinations in Parkinson’s disease: A multimodal imaging study

H. Bejr-kasem, J. Pagonabarraga, S. Martinez-Horta, F. Sampedro, J. Marin-Lahoz, J. Perez-Perez, A. Horta-Barba, B. Pascual-Sedano, J. Kulisevsky (Barcelona, Spain)

1:15pm-2:45pm

Neural Correlates Underlying Reward Processing and Decision-Making in Impulse Control Disorder in Parkinson´s Disease

I. Navalpotro-Gomez, P. Paz-Alonso, P. Boddy, M. Delgado-Alvarado, H. Jimenez-Urbieta, A. Quiroga-Varela, B. Gago, M. Carreiras, M.C. Rodriguez-Oroz (San Sebastian, Spain)

1:15pm-2:45pm

Non-motor symptom burden is associated with thalamic atrophy in Parkinson’s disease

F. Niccolini, H. Wilson, B. Giordano, K. Diamantopoulos, G. Pagano, K. Ray Chaudhuri, M. Politis (London, United Kingdom)

1:15pm-2:45pm

Non-motor symptoms in Parkinson’s disease and putamen dopamine transporter uptake (DaTscan) uptake: a survey of 85 patients

M. Qamar, A. Sauerbier, A. Rizos, K. Chaudhuri (London, United Kingdom)

1:15pm-2:45pm

Olfactory Impairment in Parkinson’s Disease and White Matter Abnormalities in Central Olfactory Areas

S. Sobhani, M. Aarabi (Tehran, Islamic Republic of Iran)

1:15pm-2:45pm

Parkinson’s disease with visual hallucination: optic radiation abnormalities on phase difference-enhanced imaging (PADRE)

M. Miyata, S. Kakeda, T. Yoneda, H. Narimatsu, T. Sato, K. Okada, H. Adachi, Y. Korogi (Kitakyushu, Japan)

1:15pm-2:45pm

Patterns of Striatal DAT Binding Loss in a Progressing Parkinson Disease (PD) Cohort: Four year PPMI Follow-up

J. Seibyl, K. Marek (New Haven, CT, USA)

1:15pm-2:45pm

Persistent L-Dopa Responsive Hemiparkinsonism After Cryptococcoal Meningoencephalitis in an Immunocompetent Man

G. Fabiani, R. Filho, F. Germiniani, H. Teive (Curitiba, Brazil)

1:15pm-2:45pm

Post-movement beta rebound inhibits future movement

E. Rhodes, A. Kharko, W. Gaetz, S. Hall (Plymouth, United Kingdom)

1:15pm-2:45pm

Prospective Analysis of Morphological Markers of Development of Impulsive Compulsive Behaviors in De Novo Parkinson’s Disease

L. Ricciardi, C. Lambert, R. De Micco, F. Morgante, M. Edwards (London, United Kingdom)

1:15pm-2:45pm

Relationship between non-motor symptoms and dopamine transporter activity in Parkinson’ s disease

M. Iijima, H. Yoshizawa, Y. Uchiyama, K. Abe, K. Kitagawa (Tokyo, Japan)

1:15pm-2:45pm

Resting state functional connectivity in PD patients with and without Freezing of gait

K. Bharti, A. Suppa, N. Upadhyay, S. Pietracupa, G. Leodori, A. Zampogna, C. Gianni, N. Petsas, A. Berardelli, P. Pantano (Rome, Italy)

1:15pm-2:45pm

Resting state modulations of EEG low frequency bands in Parkinson’s disease.

A. Pal, N. Mehta, R. Sharma (New Delhi, India)

1:15pm-2:45pm

Serotonergic, Dopaminergic Disruptions and Related Non-Motor Features Throughout the Course of Parkinson’s Disease: A Transversal PET Study

A. Maillet, E. Météreau, E. Favre, E. Lhommée, H. Klinger, D. Le Bars, A. Castrioto, V. Sgambato-Faure, L. Tremblay, E. Broussolle, P. Krack, S. Thobois (Lyon, France)

1:15pm-2:45pm

Serotonin–to–dopamine transporter ratios in Parkinson’s dyskinesias: the longitudinal study

A.-A. Roussakis, N. Lao-Kaim, A. Martin-Bastida, N. Valle-Guzman, M. Politis, T. Foltynie, R. Barker, P. Piccini (London, United Kingdom)

1:15pm-2:45pm

Signal intensity of cerebral gyri in corticobasal degeneration on phase difference enhanced MR images: Comparison with progressive supranuclear palsy and Parkinson’s disease

M. Miyata, S. Kakeda, T. Yoneda, S. Ide, K. Watanabe, J. Moriya, H. Narimatsu, T. Sato, K. Okada, H. Adachi, Y. Korogi (Kitakyushu, Japan)

1:15pm-2:45pm

Sleep disturbance may alter white matter and resting state functional connectivities in Parkinson’s disease

S.J. Chung, Y.-H. Choi, H. Kwon, Y.-H. Park, H.J. Yun, H.S. Yoo, Y.H. Sohn, J.-M. Lee, P.H. Lee (Seoul, Republic of Korea)

1:15pm-2:45pm

SPECT imaging of striatal DAT availability in Parkinson’s: changes over time and relevance to dyskinesias

A.-A. Roussakis, D. Towey, P. Piccini (London, United Kingdom)

1:15pm-2:45pm

Speech difficulties are linked to striatal dopaminergic deficits and cognitive decline in early de novo patients with Parkinson’s disease

S. Polychronis, F. Niccolini, G. Pagano, M. Politis (London, United Kingdom)

1:15pm-2:45pm

Striato-cortical connections in Parkinson’s and Alzheimer’s diseases: relation to cognition

I. Rektorova, L. Anderkova, M. Barton (Brno, Czech Republic)

1:15pm-2:45pm

Structural and Functional Correlates of Anxiety in Parkinson’s disease.

F. Růžička, T. Ballarini, O. Bezdíček, J. Roth, T. Sieger, J. Vymazal, E. Růžička, K. Mueller, R. Jech (Prague, Czech Republic)

1:15pm-2:45pm

Structural brain abnormalities associated with preclinical cognitive impairment in Idiopathic Parkinson’s Disease.

C. Lambert, O. Williams, L. Ricciardi, F. Morgante, T. Barrick, M. Edwards (London, United Kingdom)

1:15pm-2:45pm

Subcortical local shape volume analysis of progressive mild cognitive impairment in Parkinson`s disease

S.J. Chung, J.-H. Shin, K.h. Cho, Y. Lee, H.S. Yoo, S.J. Chung, Y.H. Sohn, J.-K. Seong, P.H. Lee (Seoul, Republic of Korea)

1:15pm-2:45pm

Substantia nigra area evaluated by neuromelanin-sensitive MRI as an imaging biomarker of disease progression in Parkinson’s disease

M. Fabbri, S. Reimão, M. Carbalho, R. Nunes, D. Abreu, L. Guedes, R. Bouça, P. Lobo, C. Godinho, M. Coelho, N. Gonçalves, M. Rosa, A. Antonini, J. Ferreira (Lisbon, Portugal)

1:15pm-2:45pm

Swallowing difficulties and Parkinson’s disease

S. Polychronis, G. Dervenoulas, G. Pagano, F. Niccolini, M. Politis (London, United Kingdom)

1:15pm-2:45pm

The brain plasticity for controlling reach-to-grasp functions of Parkinson’s disease

J. Tretriluxana, S. Tretriluxana, J. Thanakamchokchai, A. Nanbancha, A. Pisarnpong (Nakhon Pathom, Thailand)

1:15pm-2:45pm

The combination of the MIBG myocardial scintigraphy and DATSPECT contributes to the diagnosis of PD and other related disorders.

S. Tada, H. Ohtsubo, Y. Yamanishi, N. Miyaue, R. Ando, H. Yabe, N. Nishikawa, M. Nagai, M. Miyagawa, M. Nomoto (Ehime, Japan)

1:15pm-2:45pm

The effect of expectation on Parkinson’s Disease: an EEG study

E. Carlino, A. Piedimonte, G. Guerra, A. Romagnolo, E. Frisaldi, S. Vighetti, L. Lopiano (Turin, Italy)

1:15pm-2:45pm

The influence of LRRK2 mutations on cholinergic system in manifest and prodromal stage of Parkinson’s disease: a positron emission tomography study

S. [email protected], D. Wile, J. Fu, J. Valerio, E. Shahinfard, S. McCormick, R. Mabrouk, N. Vafai, J. McKenzie, N. Neilson, A. Perez-Soriano, J. Arena, M. Cherkasova, J. Zhang, C. Zabetian, J. Aasly, Z. Wszolek, M. McKeown, V. Sossi, A. Stoessl (Beijing, China)

1:15pm-2:45pm

The involvement of primary olfactory cortex in olfactory deficits in early-stage Parkinson’s disease

J. Wang, T. Subramanian, Q. Yang (Hershey, PA, USA)

1:15pm-2:45pm

The prevalence of cerebral microbleeds in patients with Parkinson’s disease and multiple system atrophy

J.-M. Kim (Seongnam, Republic of Korea)

1:15pm-2:45pm

The Putamen to Caudate Nucleus Ratio: A Simple Surrogate Marker for Dopaminergic Volume in Putamen

J.J. Lee, Y.H. Sohn (Goyang-si, Republic of Korea)

1:15pm-2:45pm

The Relative Preservation of the Dopaminergic Neuroal Loss of Patients with Parkinson’s Disease Having Dopamine-Unresponsive Resting Tremor

S. You, H.W. Kim (Daegu, Republic of Korea)

1:15pm-2:45pm

The Role of MRI and DaTscan in Vascular Parkinsonism: A Case Report

A. Tran, M. Amin, R. Burns (Phoenix, AZ, USA)

1:15pm-2:45pm

The role of phosphodiesterase 4 in sleep disturbances in Parkinson’s disease

H. Wilson, G. Pagano, F. Niccolini, N. Muhlert, C. Coello, M. Mehta, G. Searle, R. Gunn, E. Rabiner, T. Foltynie, M. Politis (London, United Kingdom)

1:15pm-2:45pm

U-shaped dopamine resting state connectivity response function related to working memory performance in adults with early-stage Parkinson’s disease

A. Metcalfe, S. Udow, H. Sharmarke, Z. Shirzadi, D. Long, S. Duff-Canning, C. Marras, A. Lang, B. MacIntosh, M. Masellis (Toronto, ON, Canada)

1:15pm-2:45pm

Understanding neural activation in semantic fluency in Parkinson’s disease with mild cognitive impairment

J.H. Julia, K. McMahon, D. Copland, G. Byrne, A. Toft, L. Mithcell, J. O'Sullivan, N. Dissanayaka (Herston, Australia)

1:15pm-2:45pm

Utility of DaTscan Imaging in Differentiating Drug Induced Parkinsonism from IPD and Other Forms of Parkinsonism

M. Salgado, D. Panebianco, J. Muller, A. Ortega, S. (Brooklyn, NY, USA)

1:15pm-2:45pm

Utility of susceptibility weighted imaging in the objective diagnosis of idiopathic Parkinson’s Disease: Is DaTscan necessary?

R. Ellis, M. Radon, M. Bonello, M. Steiger (Liverpool, United Kingdom)

1:15pm-2:45pm

Volume analysis and localization of midbrain hyperechogenecities via TCS and MRI

A. Plate, S.-A. Ahmadi, K. Boetzel (Munich, Germany)

1:15pm-2:45pm

White Matter Microstructural Features of Motor Subtypes in De Novo, Drug Naïve Parkinson’s Disease Patient

M.-C. Wen, H. Heng, Z. Lu, Z. Xu, L.L. Chan, E.K. Tan, L. Tan (Singapore, Singapore)

1:15pm-2:45pm

Writing training enhances neural connectivity in Parkinson’s patients with micrographia

E. Nackaerts, J. Michely, E. Heremans, S. Swinnen, B. Smits-Engelsmans, W. Vandenberghe, C. Grefkes, A. Nieuwboer (Leuven, Belgium)